BACKGROUND: Prostate cancer is a genetically complex disease with locus and disease heterogeneity. The RNASEL gene and HPCX locus have been implicated in hereditary prostate cancer; however, their contributions to sporadic forms of this malignancy remain uncertain. METHODS: Associations of prostate cancer with two variants in the RNASEL gene (a founder mutation, 471delAAAG, and a non-synonymous SNP, rs486907), and with five microsatellite markers in the HPCX locus, were examined in 979 cases and 1,251 controls of Ashkenazi Jewish descent. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models. RESULTS: There was an inverse association between RNASEL rs486907 and prostate cancer in younger men (<65 years) and those with a first-degree relative with prostate cancer; men with AA genotype had ORs of 0.64 and 0.47 (both P < 0.05), respectively, in comparison to men with GG genotype. Within the HPCX region, there were positive associations for allele 135 of bG82i1.1 marker (OR = 1.77, P = 0.01) and allele 188 of DXS1205 (OR = 1.65, P = 0.02). In addition, allele 248 of marker D33 was inversely associated (OR = 0.65, P = 0.05) with Gleason score ≥7 tumors. CONCLUSIONS: Results suggest that variants in RNASEL contribute to susceptibility to early onset and familial forms of prostate cancer, whereas HPCX variants are associated with prostate cancer risk and tumor aggressiveness. The observation that a mutation predicted to completely inactivate RNASEL protein was not associated with prostate cancer, but that a missense variant was associated, suggests that the effect is due to either partial inactivation of the protein, and/or acquisition of a new protein activity.
BACKGROUND:Prostate cancer is a genetically complex disease with locus and disease heterogeneity. The RNASEL gene and HPCX locus have been implicated in hereditary prostate cancer; however, their contributions to sporadic forms of this malignancy remain uncertain. METHODS:Associations of prostate cancer with two variants in the RNASEL gene (a founder mutation, 471delAAAG, and a non-synonymous SNP, rs486907), and with five microsatellite markers in the HPCX locus, were examined in 979 cases and 1,251 controls of Ashkenazi Jewish descent. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models. RESULTS: There was an inverse association between RNASEL rs486907 and prostate cancer in younger men (<65 years) and those with a first-degree relative with prostate cancer; men with AA genotype had ORs of 0.64 and 0.47 (both P < 0.05), respectively, in comparison to men with GG genotype. Within the HPCX region, there were positive associations for allele 135 of bG82i1.1 marker (OR = 1.77, P = 0.01) and allele 188 of DXS1205 (OR = 1.65, P = 0.02). In addition, allele 248 of marker D33 was inversely associated (OR = 0.65, P = 0.05) with Gleason score ≥7 tumors. CONCLUSIONS: Results suggest that variants in RNASEL contribute to susceptibility to early onset and familial forms of prostate cancer, whereas HPCX variants are associated with prostate cancer risk and tumor aggressiveness. The observation that a mutation predicted to completely inactivate RNASEL protein was not associated with prostate cancer, but that a missense variant was associated, suggests that the effect is due to either partial inactivation of the protein, and/or acquisition of a new protein activity.
Authors: James M Farnham; Nicola J Camp; Jeff Swensen; Sean V Tavtigian; Lisa A Cannon Albright Journal: Hum Genet Date: 2004-12-08 Impact factor: 4.132
Authors: Agnes B Baffoe-Bonnie; Jeffrey R Smith; Dietrich A Stephan; Johanna Schleutker; John D Carpten; Tommi Kainu; Elizabeth M Gillanders; Mika Matikainen; Tanya M Teslovich; Teuvo Tammela; Raman Sood; Andrew M Balshem; Sheehan D Scarborough; Jianfeng Xu; William B Isaacs; Jeffrey M Trent; Olli-P Kallioniemi; Joan E Bailey-Wilson Journal: Hum Genet Date: 2005-05-20 Impact factor: 4.132
Authors: Hanna Rennert; Charnita M Zeigler-Johnson; Kathakali Addya; Matthew J Finley; Amy H Walker; Elaine Spangler; Debra G B Leonard; Alan Wein; S Bruce Malkowicz; Timothy R Rebbeck Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: Fredrik Wiklund; Björn-Anders Jonsson; Anthony J Brookes; Linda Strömqvist; Jan Adolfsson; Monica Emanuelsson; Hans-Olov Adami; Katarina Augustsson-Bälter; Henrik Grönberg Journal: Clin Cancer Res Date: 2004-11-01 Impact factor: 12.531
Authors: Jianfeng Xu; Latchezar Dimitrov; Bao-Li Chang; Tamara S Adams; Aubrey R Turner; Deborah A Meyers; Rosalind A Eeles; Douglas F Easton; William D Foulkes; Jacques Simard; Graham G Giles; John L Hopper; Lovise Mahle; Pal Moller; Tim Bishop; Chris Evans; Steve Edwards; Julia Meitz; Sarah Bullock; Questa Hope; Chih-Lin Hsieh; Jerry Halpern; Raymond N Balise; Ingrid Oakley-Girvan; Alice S Whittemore; Charles M Ewing; Marta Gielzak; Sarah D Isaacs; Patrick C Walsh; Kathleen E Wiley; William B Isaacs; Stephen N Thibodeau; Shannon K McDonnell; Julie M Cunningham; Katherine E Zarfas; Scott Hebbring; Daniel J Schaid; Danielle M Friedrichsen; Kerry Deutsch; Suzanne Kolb; Michael Badzioch; Gail P Jarvik; Marta Janer; Leroy Hood; Elaine A Ostrander; Janet L Stanford; Ethan M Lange; Jennifer L Beebe-Dimmer; Caroline E Mohai; Kathleen A Cooney; Tarja Ikonen; Agnes Baffoe-Bonnie; Henna Fredriksson; Mika P Matikainen; Teuvo Lj Tammela; Joan Bailey-Wilson; Johanna Schleutker; Christiane Maier; Kathleen Herkommer; Josef J Hoegel; Walther Vogel; Thomas Paiss; Fredrik Wiklund; Monica Emanuelsson; Elisabeth Stenman; Bjorn-Anders Jonsson; Henrik Gronberg; Nicola J Camp; James Farnham; Lisa A Cannon-Albright; Daniela Seminara Journal: Am J Hum Genet Date: 2005-06-29 Impact factor: 11.025
Authors: J Simard; M Dumont; D Labuda; D Sinnett; C Meloche; M El-Alfy; L Berger; E Lees; F Labrie; S V Tavtigian Journal: Endocr Relat Cancer Date: 2003-06 Impact factor: 5.678
Authors: Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippmann; Howard L Parnes; Paul J Dluzniewski; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz Journal: Prostate Date: 2015-06-05 Impact factor: 4.104
Authors: Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci Journal: Clin Cancer Res Date: 2013-02-04 Impact factor: 12.531
Authors: Joan E Bailey-Wilson; Erica J Childs; Cheryl D Cropp; Daniel J Schaid; Jianfeng Xu; Nicola J Camp; Lisa A Cannon-Albright; James M Farnham; Asha George; Isaac Powell; John D Carpten; Graham G Giles; John L Hopper; Gianluca Severi; Dallas R English; William D Foulkes; Lovise Mæhle; Pål Møller; Rosalind Eeles; Douglas Easton; Michelle Guy; Steve Edwards; Michael D Badzioch; Alice S Whittemore; Ingrid Oakley-Girvan; Chih-Lin Hsieh; Latchezar Dimitrov; Janet L Stanford; Danielle M Karyadi; Kerry Deutsch; Laura McIntosh; Elaine A Ostrander; Kathleen E Wiley; Sarah D Isaacs; Patrick C Walsh; Stephen N Thibodeau; Shannon K McDonnell; Scott Hebbring; Ethan M Lange; Kathleen A Cooney; Teuvo L J Tammela; Johanna Schleutker; Christiane Maier; Sylvia Bochum; Josef Hoegel; Henrik Grönberg; Fredrik Wiklund; Monica Emanuelsson; Geraldine Cancel-Tassin; Antoine Valeri; Olivier Cussenot; William B Isaacs Journal: BMC Med Genet Date: 2012-06-19 Impact factor: 2.103
Authors: Maria Jesus Alvarez-Cubero; Luis Javier Martinez-Gonzalez; Fernando Vazquez-Alonso; Maria Saiz; Juan Carlos Alvarez; Jose Antonio Lorente; Jose Manuel Cozar Journal: Springerplus Date: 2013-09-08